Higher dose of Spinraza helped spinal muscular atrophy patients, Biogen says

Biogen on Wednesday said that an experimental, higher dose of its spinal muscular atrophy drug Spinraza met the primary endpoint of a clinical trial comparing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Hims CEO says he’d rather go after rivals’ customers than buy their businesses

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) SAN FRANCISCO — For companies that advertise

January 31, 2024

Four minority-owned marijuana manufacturers join forces under one roof – The Cannabist

Related Articles Finding a physical location to open a cannabis business in Denver is challenging. Ask local Sarah Woodson and she’ll tell you it’s among

October 20, 2023

Study sheds light on progress and gaps in hepatitis C clearance cascade

Researchers described the hepatitis C virus (HCV) elimination cascade during the direct-acting antivirals (DAA) era.

July 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.